Cargando…

MON-575 Clinical Implication of Sonographic Evaluation for Immune Checkpoint Inhibitor-Related Thyroiditis: A Case Series Study

Background: Although immune-related thyroiditis induced by immune checkpoint inhibitors (ICIs) is a common adverse event, its natural course and sequelae is not well understood. In this study, we aimed to evaluate sonographic features of thyroid in patients presenting thyrotoxicosis after ICI treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, A Ram, Yoon, Jee Hee, Kim, Hee Kyung, Kang, Ho-Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550634/
http://dx.doi.org/10.1210/js.2019-MON-575
_version_ 1783424225182220288
author Hong, A Ram
Yoon, Jee Hee
Kim, Hee Kyung
Kang, Ho-Cheol
author_facet Hong, A Ram
Yoon, Jee Hee
Kim, Hee Kyung
Kang, Ho-Cheol
author_sort Hong, A Ram
collection PubMed
description Background: Although immune-related thyroiditis induced by immune checkpoint inhibitors (ICIs) is a common adverse event, its natural course and sequelae is not well understood. In this study, we aimed to evaluate sonographic features of thyroid in patients presenting thyrotoxicosis after ICI treatment, and to figure out whether the findings could predict the clinical course of thyroiditis. Materials and Methods: We analyzed five consecutive cases with thyrotoxicosis associated with ICI, which modulates cytotoxic T-lymphocyte antigen-4, programmed cell death protein-1, or it ligand PD-L1 in a single tertiary cancer center. All patients had normal baseline thyroid function prior to starting ICIs. Thyroid function was evaluated until 24 weeks after starting ICIs. Results: ICIs included pembrolizumab (n=2), durvalumab (n=2), and atezolizumab (n=1). Cancer diagnoses observed were lung cancer (n=3), cervix cancer (n=1), and transitional cell carcinoma (n=1). All patients presented with painless thyroiditis and 3 (60.0%) patients were asymptomatic during the thyrotoxicosis phase. Median time from starting ICI to thyrotoxicosis was 4.0 weeks. Mild enlargement of thyroid glands and low echogenicity were observed on ultrasonography in four patients (80.0%). Hypothyroidism developed in all of them at a median of 6.8 weeks after thyrotoxicosis, and these patients remained on levothyroxine at 24 weeks after ICI treatments. Anti-thyroglobulin antibodies (TgAbs) and/or anti-thyroid peroxidase Abs were positive in three of them (75.0%). One patient (20.0%) showed normal thyroid glands on ultrasonography and was positive for TgAb. She developed hypothyroidism at 18 weeks after thyrotoxicosis and remained on levothyroxine at 24 weeks after ICI. No patient with Graves’ disease was observed. Conclusion: In the present cases, ICI-induced thyrotoxicosis is associated with painless thyroiditis. Sonographic features suggestive of chronic thyroiditis seem to be relevant to the development of hypothyroidism. However, even if sonographic features are normal, progression of thyrotoxicosis to hypothyroidism cannot be excluded.
format Online
Article
Text
id pubmed-6550634
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65506342019-06-13 MON-575 Clinical Implication of Sonographic Evaluation for Immune Checkpoint Inhibitor-Related Thyroiditis: A Case Series Study Hong, A Ram Yoon, Jee Hee Kim, Hee Kyung Kang, Ho-Cheol J Endocr Soc Thyroid Background: Although immune-related thyroiditis induced by immune checkpoint inhibitors (ICIs) is a common adverse event, its natural course and sequelae is not well understood. In this study, we aimed to evaluate sonographic features of thyroid in patients presenting thyrotoxicosis after ICI treatment, and to figure out whether the findings could predict the clinical course of thyroiditis. Materials and Methods: We analyzed five consecutive cases with thyrotoxicosis associated with ICI, which modulates cytotoxic T-lymphocyte antigen-4, programmed cell death protein-1, or it ligand PD-L1 in a single tertiary cancer center. All patients had normal baseline thyroid function prior to starting ICIs. Thyroid function was evaluated until 24 weeks after starting ICIs. Results: ICIs included pembrolizumab (n=2), durvalumab (n=2), and atezolizumab (n=1). Cancer diagnoses observed were lung cancer (n=3), cervix cancer (n=1), and transitional cell carcinoma (n=1). All patients presented with painless thyroiditis and 3 (60.0%) patients were asymptomatic during the thyrotoxicosis phase. Median time from starting ICI to thyrotoxicosis was 4.0 weeks. Mild enlargement of thyroid glands and low echogenicity were observed on ultrasonography in four patients (80.0%). Hypothyroidism developed in all of them at a median of 6.8 weeks after thyrotoxicosis, and these patients remained on levothyroxine at 24 weeks after ICI treatments. Anti-thyroglobulin antibodies (TgAbs) and/or anti-thyroid peroxidase Abs were positive in three of them (75.0%). One patient (20.0%) showed normal thyroid glands on ultrasonography and was positive for TgAb. She developed hypothyroidism at 18 weeks after thyrotoxicosis and remained on levothyroxine at 24 weeks after ICI. No patient with Graves’ disease was observed. Conclusion: In the present cases, ICI-induced thyrotoxicosis is associated with painless thyroiditis. Sonographic features suggestive of chronic thyroiditis seem to be relevant to the development of hypothyroidism. However, even if sonographic features are normal, progression of thyrotoxicosis to hypothyroidism cannot be excluded. Endocrine Society 2019-04-30 /pmc/articles/PMC6550634/ http://dx.doi.org/10.1210/js.2019-MON-575 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Thyroid
Hong, A Ram
Yoon, Jee Hee
Kim, Hee Kyung
Kang, Ho-Cheol
MON-575 Clinical Implication of Sonographic Evaluation for Immune Checkpoint Inhibitor-Related Thyroiditis: A Case Series Study
title MON-575 Clinical Implication of Sonographic Evaluation for Immune Checkpoint Inhibitor-Related Thyroiditis: A Case Series Study
title_full MON-575 Clinical Implication of Sonographic Evaluation for Immune Checkpoint Inhibitor-Related Thyroiditis: A Case Series Study
title_fullStr MON-575 Clinical Implication of Sonographic Evaluation for Immune Checkpoint Inhibitor-Related Thyroiditis: A Case Series Study
title_full_unstemmed MON-575 Clinical Implication of Sonographic Evaluation for Immune Checkpoint Inhibitor-Related Thyroiditis: A Case Series Study
title_short MON-575 Clinical Implication of Sonographic Evaluation for Immune Checkpoint Inhibitor-Related Thyroiditis: A Case Series Study
title_sort mon-575 clinical implication of sonographic evaluation for immune checkpoint inhibitor-related thyroiditis: a case series study
topic Thyroid
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550634/
http://dx.doi.org/10.1210/js.2019-MON-575
work_keys_str_mv AT hongaram mon575clinicalimplicationofsonographicevaluationforimmunecheckpointinhibitorrelatedthyroiditisacaseseriesstudy
AT yoonjeehee mon575clinicalimplicationofsonographicevaluationforimmunecheckpointinhibitorrelatedthyroiditisacaseseriesstudy
AT kimheekyung mon575clinicalimplicationofsonographicevaluationforimmunecheckpointinhibitorrelatedthyroiditisacaseseriesstudy
AT kanghocheol mon575clinicalimplicationofsonographicevaluationforimmunecheckpointinhibitorrelatedthyroiditisacaseseriesstudy